Clinical Trial Update: A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating ocrelizumab for leptomeningeal inflammation in multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis | Phase 4 | Status: WITHDRAWN